Great Basin Corporation Initiates First Clinical Trial for C. Difficile Molecular Diagnostic Test
SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Corporation, a privately held life sciences company developing novel, sample-to-result molecular diagnostic solutions, today announced the initiation of its first clinical trial evaluating its molecular diagnostic test for Clostridium difficile (C. diff), one of the most common and deadly hospital-acquired infections (HAIs).